Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Antibody Comparison, 2011
    Antibody Testing in Postmortem Human Brain

    Objective/Rationale: 
    Mutations in the gene for LRRK2 are the most common genetic cause for Parkinson’s disease (PD) and therefore the LRRK2 protein appears to be important for normal brain function...

  • Research Grant, 2011
    LRRK2 Antibody Comparison 2011

    Objective/Rationale: 
    LRRK2 (Leucine-Rich Repeat Kinase 2) is a protein thought to be involved in regulating signaling pathways in cells. Mutations in the gene for LRRK2 are associated with some...

  • Target Validation, 2011
    Role of PARK18 in Parkinson's Disease

    Objective/Rationale: 
    PARK18 is a genetic marker that was recently found to be associated with susceptibility to Parkinson’s disease (PD). The marker is encoded within the HLA-DRA gene, a gene that...

  • MJFF Research Grant, 2011
    fMRI of First Degree Relatives of LRRK2 Positive PD Patients

    Objective/Rationale:

    First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in Parkinson’s disease (PD) patients who recently converted into a diseased...

  • Repositioning Drugs for PD, 2011
    Fasudil as a Novel Therapeutic for the Treatment of Parkinson's Disease

    Objective/Rationale: 
    The therapeutic drug we will repurpose for Parkinson’s disease (PD) is fasudil, a kinase inhibitor with an impressive safety profile in humans. The target of fasudil is highly...

  • Repositioning Drugs for PD, 2011
    DPP-4 Inhibitors for the Treatment of Parkinson's Disease

    Objective/Rationale: 
    This is a collaborative research project between three organizations, NIDA, NIA and Pfizer, focused towards characterizing whether gliptins, a well-tolerated drug class effective...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.